Latest Insider Transactions at Sarepta Therapeutics, Inc. (SRPT)
This section provides a real-time view of insider transactions for Sarepta Therapeutics, Inc. (SRPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Sarepta Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Sarepta Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2025
|
Richard Barry |
BUY
Exercise of conversion of derivative security
|
Direct |
12,350
+0.41%
|
$395,200
$32.63 P/Share
|
|
May 13
2025
|
Richard Barry |
BUY
Exercise of conversion of derivative security
|
Direct |
20,246
+0.34%
|
$384,674
$19.45 P/Share
|
|
Mar 12
2025
|
Claude Nicaise |
SELL
Open market or private sale
|
Direct |
2,491
-8.22%
|
$246,609
$99.64 P/Share
|
|
Mar 12
2025
|
Claude Nicaise |
BUY
Exercise of conversion of derivative security
|
Direct |
9,746
+24.34%
|
$243,650
$25.18 P/Share
|
|
Mar 10
2025
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+1.22%
|
-
|
|
Mar 10
2025
|
Claude Nicaise |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+10.39%
|
-
|
|
Mar 10
2025
|
Richard Barry |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+0.08%
|
-
|
|
Mar 10
2025
|
Louise Rodino Klapac Head of R&D, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
8,276
+8.91%
|
-
|
|
Mar 10
2025
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,463
-2.19%
|
$346,300
$100.13 P/Share
|
|
Mar 10
2025
|
Dallan Murray Chief Customer Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,276
+17.81%
|
-
|
|
Mar 10
2025
|
Dallan Murray Chief Customer Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,733
-5.67%
|
$373,300
$100.13 P/Share
|
|
Mar 10
2025
|
Bilal Arif Chief Tech Ops Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,276
+20.3%
|
-
|
|
Mar 10
2025
|
Bilal Arif Chief Tech Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
523
-2.11%
|
$52,300
$100.13 P/Share
|
|
Mar 10
2025
|
Stephen Mayo |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+20.93%
|
-
|
|
Mar 10
2025
|
Hans Lennart Rudolf Wigzell |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+8.63%
|
-
|
|
Mar 10
2025
|
Ian Michael Estepan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,276
+11.67%
|
-
|
|
Mar 10
2025
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,941
-3.43%
|
$394,100
$100.13 P/Share
|
|
Mar 10
2025
|
Cristin Rothfuss EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,276
+28.16%
|
-
|
|
Mar 10
2025
|
Cristin Rothfuss EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
491
-3.68%
|
$49,100
$100.13 P/Share
|
|
Mar 10
2025
|
Michael Andrew Chambers |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+18.27%
|
-
|
|
Mar 10
2025
|
Kathryn Jean Boor |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+22.38%
|
-
|
|
Mar 10
2025
|
Deirdre P Connelly |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+31.32%
|
-
|
|
Mar 07
2025
|
Louise Rodino Klapac Head of R&D, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+6.45%
|
-
|
|
Mar 07
2025
|
Dallan Murray Chief Customer Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+14.05%
|
-
|
|
Mar 07
2025
|
Ian Michael Estepan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+8.62%
|
-
|
|
Mar 07
2025
|
Bilal Arif Chief Tech Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,035
-13.57%
|
$930,605
$103.7 P/Share
|
|
Mar 07
2025
|
Dallan Murray Chief Customer Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,162
-12.45%
|
$943,686
$103.7 P/Share
|
|
Mar 07
2025
|
Cristin Rothfuss EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,478
-5.67%
|
$152,234
$103.7 P/Share
|
|
Mar 07
2025
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,504
-5.16%
|
$875,912
$103.7 P/Share
|
|
Mar 07
2025
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,679
-7.82%
|
$996,937
$103.7 P/Share
|
|
Mar 06
2025
|
Bilal Arif Chief Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+34.13%
|
-
|
|
Mar 06
2025
|
Dallan Murray Chief Customer Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+31.92%
|
-
|
|
Mar 06
2025
|
Louise Rodino Klapac Head of R&D, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+17.44%
|
-
|
|
Mar 06
2025
|
Ian Michael Estepan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+21.89%
|
-
|
|
Mar 04
2025
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,704
-2.54%
|
$172,104
$101.34 P/Share
|
|
Mar 04
2025
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,370
-2.96%
|
$138,370
$101.34 P/Share
|
|
Mar 04
2025
|
Dallan Murray Chief Customer Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,685
-7.84%
|
$170,185
$101.34 P/Share
|
|
Mar 04
2025
|
Bilal Arif Chief Tech Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
514
-1.54%
|
$51,914
$101.34 P/Share
|
|
Mar 04
2025
|
Cristin Rothfuss EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
584
-2.17%
|
$58,984
$101.34 P/Share
|
|
Mar 03
2025
|
Cristin Rothfuss EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
391
-2.79%
|
$40,273
$103.77 P/Share
|
|
Mar 03
2025
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
715
-1.06%
|
$73,645
$103.77 P/Share
|
|
Mar 03
2025
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
557
-1.19%
|
$57,371
$103.77 P/Share
|
|
Mar 03
2025
|
Bilal Arif Chief Tech Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
719
-4.11%
|
$74,057
$103.77 P/Share
|
|
Mar 03
2025
|
Dallan Murray Chief Customer Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
711
-3.2%
|
$73,233
$103.77 P/Share
|
|
Jan 29
2025
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,613
-5.28%
|
$305,721
$117.51 P/Share
|
|
Jan 29
2025
|
Ian Michael Estepan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,800
+12.97%
|
$189,600
$12.0 P/Share
|
|
Dec 27
2024
|
Ian Michael Estepan Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
250
-0.74%
|
-
|
|
Dec 12
2024
|
Hans Lennart Rudolf Wigzell |
SELL
Open market or private sale
|
Direct |
10,500
-31.49%
|
$1,302,000
$124.84 P/Share
|
|
Dec 12
2024
|
Hans Lennart Rudolf Wigzell |
BUY
Exercise of conversion of derivative security
|
Direct |
10,500
+23.95%
|
$136,500
$13.71 P/Share
|
|
Dec 05
2024
|
Kathryn Jean Boor |
SELL
Open market or private sale
|
Direct |
1,636
-21.77%
|
$204,500
$125.55 P/Share
|